Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Immune Globulin Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 3797-D

    Medicare Part B Step Therapy Immune Globulins

    Customize your policy alerts

    Sign up for zing_health Policy 3797-D alerts

    Get alerted when Policy 3797-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of preferred and non-preferred immune globulin products under Medicare Part B Advanced Biosimilars First. Non-preferred products require prior authorization and are covered for new starts when specified clinical exception criteria are met.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Immune Globulins
    Policy CodePolicy 3797-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization through the exception process for non-preferred immune globulin products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Preferred immune globulin products
    9Non-preferred immune globulin products
    365 daysPrior-use lookback period
    3Preferred products required for intolerance exception

    Non-Preferred Product Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-preferred product coverage criteria

    Coverage for a non-preferred product is provided when either of the following criteria is met:

    Non-preferred product coverage exception

    • Recent prior use: Member has received treatment with the requested non-preferred product in the past 365 days.within the past 365 days
    • Intolerance to preferred products: Member has a documented intolerable adverse event with at least 3 preferred products.at least 3 preferred products

      The adverse event must be documented as intolerable.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required for Non-Preferred Products

    Prior authorization is required for non-preferred immune globulin products. Coverage is reviewed through the exception process when clinical circumstances exclude use of a preferred product or the member's previous product use supports an exception.

    • The coverage review will determine whether a clinical exception can be made for the requested non-preferred product.
    • This program applies to the immune globulin products specified in the policy and aligns with Medicare Part B and Medicare Part B Advanced Biosimilars First.
    Prior Authorization

    Exception Review for New Treatment

    For members who are new to treatment with a non-preferred product, submit a prior authorization request for exception review. Coverage may be granted when clinical circumstances would exclude use of the preferred product.

    • The exception process applies when the non-preferred product is being used for the first time in a member new to treatment with that product.
    • Document the clinical circumstances supporting why a preferred product cannot be used.
    Documentation Required

    Document Prior Use or Preferred-Product Intolerance

    Support the exception request with documentation of the member's relevant treatment history or adverse events.

    • Document treatment with the requested non-preferred product within the past 365 days; or
    • Document an intolerable adverse event with at least 3 preferred products.
    Denial Risk

    Exception Criteria Not Met

    Coverage for the non-preferred product may be denied when the exception criteria are not met.

    • No documented treatment with the non-preferred product in the past 365 days; and
    • No documented intolerable adverse event with at least 3 preferred products.

    Policy Background

    This policy manages Medicare Part B coverage of immune globulin products under the Advanced Biosimilars First program. It uses a preferred-product strategy for immune globulins and provides an exception pathway for non-preferred products through prior authorization when clinical circumstances support their use, including prior treatment or documented intolerance to preferred products.

    Key Definition

    New to treatment with a non-preferred product
    DefinitionA member who is beginning treatment with a non-preferred product for the first time under this program.
    Program contextThe program applies to members who are new to treatment with a non-preferred product for the first time.
    Coverage reviewCoverage for non-preferred products is based on clinical circumstances that would exclude use of the preferred product and may be based on previous use of a product.

    Initial Therapy With a Non-Preferred Product

    Initial therapy with a non-preferred product

    This program applies to members who are new to treatment with a non-preferred product for the first time. Coverage is provided when either of the following criteria is met:

    Initial non-preferred product exception

    • Prior treatment: Member has received treatment with the requested non-preferred product in the past 365 days.within the past 365 days
    • Preferred-product intolerance: Member has a documented intolerable adverse event with at least 3 preferred products.at least 3 preferred products

      The adverse event must be documented as intolerable.

    Step Therapy Requirements

    PathwayRequirementCoverage
    Prior treatmentMember has received treatment with the requested non-preferred product within the past 365 days.Covered
    Preferred-product intoleranceMember has a documented intolerable adverse event with at least 3 preferred products.Covered

    Product Route and Site-of-Care Classification

    Note

    Verify route classification for preferred products

    Use the policy’s site-of-care classifications when identifying the requested product’s route. Flebogamma, Octagam, and Privigen are intravenous; Gammaked and Gamunex-C are subcutaneous or intravenous.

    • Flebogamma — intravenous
    • Octagam — intravenous
    • Privigen — intravenous
    • Gammaked — subcutaneous/intravenous
    • Gamunex-C — subcutaneous/intravenous
    Note

    Verify route classification for non-preferred products

    Use the policy’s site-of-care classifications when identifying the requested product’s route. Asceniv, Bivigam, Gammaplex, and Panzyga are intravenous; Cutaquig, Cuvitru, HyQvia, and Xembify are subcutaneous.

    • Asceniv — intravenous
    • Bivigam — intravenous
    • Gammaplex — intravenous
    • Panzyga — intravenous
    • Cutaquig — subcutaneous
    • Cuvitru — subcutaneous
    • HyQvia — subcutaneous
    • Xembify — subcutaneous
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Immune Globulins
    Policy CodePolicy 3797-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization through the exception process for non-preferred immune globulin products.
    SourceLink
    On This Page
    Non-Preferred Product Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionInitial Therapy With a Non-Preferred ProductStep Therapy RequirementsProduct Route and Site-of-Care Classification